BelleTorus Corporation (“Belle.ai”) offers the world’s most robust AI platform for evaluating and tracking skin diseases and conditions. Our skin AI platform identifies more than one thousand skin conditions and variations, including skin cancer, and measures the severity of autoimmune and inflammatory conditions such as acne, psoriasis, eczema, vitiligo, and alopecia areata. Using smartphone photos taken by patients or providers, Belle delivers an objective, easy-to-use system for identifying skin conditions, and for tracking how they progress and respond to treatments. Belle enables an unprecedented level of digital engagement among all participants in skin health and wellness, with applications available for healthcare providers, patient clinical trials and monitoring, and consumer skin care.